You are here

Our science / Clinical Trials / Find a Trial / NCT00857571

A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

Back to Search Print Save as PDF Bookmark Trial

NCT00857571

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Singapore, , 188770 Singapore
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
21-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male and female volunteers.

- Female volunteers have to be of non-childbearing potential

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at time of dosing).

- Any condition possibly affecting drug absorption (eg, gastrectomy).

- A positive urine drug screen.

NCT00857571
Pfizer
Terminated
A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Healthy Volunteers
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
NCT03184168
Males
18+
Years
Madison, Wisconsin
Normal Healthy
Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects
NCT02871037
All Genders
18+
Years
New Haven, Connecticut
Healthy
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512
NCT03146065
All Genders
18+
Years
Brussels,
Healthy
Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects
NCT03534648
All Genders
18+
Years
Brussels,
A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.
An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.
The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Healthy
  • Drug: 150 mg Suspension
    Single oral dose of 150 mg of PF-02413873 suspension
  • Drug: 30 mg Suspension
    Single oral dose of 30 mg of PF-02413873 suspension
  • Drug: 400 mg Suspension
    Single oral dose of 400 mg of PF-02413873 suspension
  • Drug: 5 mg Suspension
    Single oral dose of 5 mg of PF-02413873 suspension
  • Drug: 750 mg Suspension
    Single oral dose of 750 mg of PF-02413873 suspension
  • Drug: 150 mg Tablet
    Single oral dose of 150 mg of PF-02413873 tablets
  • Drug: 30 mg Tablet
    Single oral dose of 30 mg of PF-02413873 tablets
  • Drug: 400 mg Tablet
    Single oral dose of 400 mg of PF-02413873 tablets
  • Drug: 5 mg Tablet
    Single oral dose of 5 mg of PF-02413873 tablets
  • Drug: 750 mg Tablet
    Single oral dose of 750 mg of PF-02413873 tablets
  • Experimental: Suspension
    PF-02413873 suspension
    Interventions:
    • Drug: 150 mg Suspension
    • Drug: 30 mg Suspension
    • Drug: 400 mg Suspension
    • Drug: 5 mg Suspension
    • Drug: 750 mg Suspension
  • Experimental: Tablet
    PF-02413873 Phase 2 Tablets
    Interventions:
    • Drug: 150 mg Tablet
    • Drug: 30 mg Tablet
    • Drug: 400 mg Tablet
    • Drug: 5 mg Tablet
    • Drug: 750 mg Tablet
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
30
May 2009
May 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male and female volunteers.
  • Female volunteers have to be of non-childbearing potential

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • A positive urine drug screen.
Sexes Eligible for Study: All
21 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Singapore
 
 
NCT00857571
B0461003
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now